Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation

Sameer Bansilal,Zachary Bloomgarden,Jonathan L. Halperin,Anne S. Hellkamp,Yuliya Lokhnygina,Günter Breithardt,Graeme J. Hankey,Christopher C. Nessel,Daniel E. Singer,Scott D. Berkowitz,Jonathan P. Piccini,Kenneth W. Mahaffey

semanticscholar（2015）

引用 0|浏览0

暂无评分

摘要

Citation for published version: Bansilal, S, Bloomgarden, Z, Halperin, JL, Hellkamp, AS, Lokhnygina, Y, Patel, MR, Becker, RC, Breithardt, G, Hacke, W, Hankey, GJ, Nessel, CC, Singer, DE, Berkowitz, SD, Piccini, JP, Mahaffey, KW, Fox, KAA & ROCKET AF Steering Committee and Investigators 2015, 'Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)' The American Heart Journal, vol. 170, no. 4, pp. 675-682.e8. DOI: 10.1016/j.ahj.2015.07.006

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要